Results 241 to 250 of about 499,895 (395)

Baseline characteristics of contemporary trial participants with heart failure and reduced ejection fraction: The VICTOR trial

open access: yesEuropean Journal of Heart Failure, EarlyView.
Baseline characteristics for the vericiguat global study in participants with chronic heart failure (VICTOR) trial. ARNI, angiotensin receptor/neprilysin inhibitor; CRT, cardiac resynchronization therapy; eGFR, estimated glomerular filtration rate; GDMT, guideline‐directed medical therapy; HF, heart failure; HFrEF, heart failure with reduced ejection ...
Clara I. Saldarriaga   +21 more
wiley   +1 more source

Remote pulmonary artery pressure‐guided management of patients with heart failure: A clinical consensus statement of the Heart Failure Association (HFA) of the ESC

open access: yesEuropean Journal of Heart Failure, EarlyView.
Abstract Episodes of worsening heart failure (HF) are a major cause of unplanned hospitalizations. Their onset is usually preceded by an early increase in intracardiac pressures with subsequent worsening of symptoms due to congestion. Implantable devices allowing daily remote pulmonary artery pressure (PAP) monitoring are useful to identify early ...
Antoni Bayes‐Genis   +13 more
wiley   +1 more source

Longitudinal Outcomes of Left Ventricular Outflow Tract Obstruction in Aortic Stenosis Versus Hypertrophic Obstructive Cardiomyopathy. [PDF]

open access: yesMedicina (Kaunas)
Ong JY   +10 more
europepmc   +1 more source

Effect of metoprolol in hypertrophic obstructive cardiomyopathy patients after alcohol septal ablation. [PDF]

open access: yesInt J Cardiol Heart Vasc, 2023
Hnátová H   +4 more
europepmc   +1 more source

Effects of Metoprolol on Exercise Hemodynamics in Patients With Obstructive Hypertrophic Cardiomyopathy.

open access: yesJournal of the American College of Cardiology, 2022
A. Dybro   +6 more
semanticscholar   +1 more source

Update on preclinical models of cancer therapy‐related cardiac dysfunction: Challenges and perspectives. A scientific statement of the Heart Failure Association (HFA) of the ESC, the ESC Council of Cardio‐Oncology, and the ESC Working Group on Cellular Biology of the Heart

open access: yesEuropean Journal of Heart Failure, EarlyView.
New anticancer therapies with potential cardiovascular side effects are continuously being introduced into clinical practice, with new and often unexpected toxicities becoming apparent only after clinical introduction. These unknown toxicities should be identified and understood beforehand to better prepare patients and physicians, enabling the ...
Alessandra Ghigo   +22 more
wiley   +1 more source

Home - About - Disclaimer - Privacy